EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Safety and Efficacy of Vaptans in the Treatment of Hyponatremia from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A Systematic Review and Meta-Analysis

Pajaree Krisanapan iD, Supawit Tangpanithandee iD, Charat Thongprayoon, Pattharawin Pattharanitima iD, Andrea Kleindienst iD, Jing Miao iD, Iasmina M Craici, Michael A Mao iD, Wisit Cheungpasitporn iD

Journal of Clinical Medicine · 24.08.2023 · 12 (17) · 5483

DOI: 10.3390/jcm12175483 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.08.2023. Verfasst von Pajaree Krisanapan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The utilization of vasopressin receptor antagonists, known as vaptans, in the management of hyponatremia among patients afflicted with the syndrome of inappropriate antidiuretic hormone (SIADH) remains a contentious subject. This meta-analysis aimed to evaluate the safety and efficacy of vaptans for treating chronic hyponatremia in adult SIADH patients. Clinical trials and observational studies were identified by a systematic search using MEDLINE, EMBASE, and Cochrane Database from inception through September 2022. The inclusion criteria were the studies that reported vaptans’ safety or efficacy outcomes compared to placebo or standard therapies. The study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD 42022357307). Five studies were identified, comprising three RCTs and two cohort studies, enrolling a total of 1840 participants. Regarding short-term efficacy on days 4–5, vaptans exhibited a significant increase in serum sodium concentration from the baseline in comparison to the control group, with a weighted mean difference of 4.77 mmol/L (95% CI, 3.57, 5.96; I2 = 34%). In terms of safety outcomes, the pooled incidence rates of overcorrection were 13.1% (95% CI 4.3, 33.6; I2 = 92%) in the vaptans group and 3.3% (95% CI 1.6, 6.6; I2 = 27%) in the control group. Despite the higher correction rate linked to vaptans, with an OR of 5.72 (95% CI 3.38, 9.70; I2 = 0%), no cases of osmotic demyelination syndrome were observed. Our meta-analysis comprehensively summarizes the efficacy and effect size of vaptans in managing SIADH. While vaptans effectively raise the serum sodium concentration compared to placebo/fluid restriction, clinicians should exercise caution regarding the potential for overcorrection.

Schlagwörter

Stichwörter der Autor:innen

SIADSIADHV2R antagonistshyponatremiasatavaptansyndrome of inappropriate antidiuresissyndrome of inappropriate antidiuretic hormone secretiontolvaptanvaptansvasopressin receptor antagonist

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand.
  • Division of Nephrology, Department of Internal Medicine, Thammasat University Hospital, Pathum Thani 12120, Thailand.
  • Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, Thailand.
  • Department of Neurosurgery, Friedrich-Alexander-University Nürnberg-Erlangen, 91054 Erlangen, Germany.
  • Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA.

ORCID-Profile: Pajaree Krisanapan, Supawit Tangpanithandee, Pattharawin Pattharanitima, Andrea Kleindienst, Jing Miao, Michael A Mao, Wisit Cheungpasitporn

Zitieren

APA

Krisanapan, P., Tangpanithandee, S., Thongprayoon, C., Pattharanitima, P., Kleindienst, A., Miao, J., Craici, I. M., Mao, M. A., & Cheungpasitporn, W. (2023). Safety and Efficacy of Vaptans in the Treatment of Hyponatremia from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 12(17), 5483. https://doi.org/10.3390/jcm12175483

Vancouver

Krisanapan P, Tangpanithandee S, Thongprayoon C, Pattharanitima P, Kleindienst A, Miao J, et al. Safety and Efficacy of Vaptans in the Treatment of Hyponatremia from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2023;12(17):5483. doi:10.3390/jcm12175483

BibTeX
@article{Krisanapan2023,
  author = {Krisanapan, Pajaree and Tangpanithandee, Supawit and Thongprayoon, Charat and Pattharanitima, Pattharawin and Kleindienst, Andrea and Miao, Jing and Craici, Iasmina M and Mao, Michael A and Cheungpasitporn, Wisit},
  title = {Safety and Efficacy of Vaptans in the Treatment of Hyponatremia from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A Systematic Review and Meta-Analysis},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {17},
  pages = {5483},
  doi = {10.3390/jcm12175483}
}
Kostenlos starten →